Please login to the form below

Not currently logged in
Email:
Password:

T-DM1

This page shows the latest T-DM1 news and features for those working in and with pharma, biotech and healthcare.

Immunotherapy and future directions in oncology

Immunotherapy and future directions in oncology

Those dendritic cells can activate cytotoxic T-cells which, after replicating, track and eradicate cancer cells. ... Kadcyla (trastuzumab emtansine, Genentech of Roche) targets HER2 receptors present in breast cancer and delivers an anti-microtubule

Latest news

  • EU backs Roche’s Kadcyla in breast cancer EU backs Roche’s Kadcyla in breast cancer

    Expectations are high for the Kadcyla, which is an antibody-drug conjugate (ADC) that combines the monoclonal antibody in Herceptin with ImmunoGen's DM1, a cytotoxic payload designed to boost its

  • Roche's Herceptin follow-up cleared in US Roche's Herceptin follow-up cleared in US

    Roche's Herceptin follow-up cleared in US. FDA approval for Kadcyla (formerly T-DM1) in breast cancer. ... The FDA has given the go-ahead to Kadcyla, formerly known as T-DM1, as a therapy for patients with HER2-positive, late-stage metastatic breast

  • Product updates from Japan

    pylori", according to the partners. Chugai Pharmaceutical has filed for approval of trastuzumab emtansine (T-DM1) - originally developed by Roche/Genentech as a follow-up to their Herceptin (trastuzumab) blockbuster - for ... Chugai has commercialisation

  • Roche delivers solid sales gain in 2012 Roche delivers solid sales gain in 2012

    Perjeta has been tipped as a future blockbuster, as has Herceptin follow-up trastuzumab emtansine ( T-DM1), which is filed in the US and Europe and expected to be on the

  • Celgene signs $500m antibody deal with Sutro Celgene signs $500m antibody deal with Sutro

    In addition, Roche is involved in the advancement of antibody-drug conjugates with T-DM1, which has caused great excitement for its potential in the treatment of breast cancer.

More from news
Approximately 4 fully matching, plus 17 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics